Literature DB >> 9844827

The optimization of helper T lymphocyte (HTL) function in vaccine development.

J Alexander1, J Fikes, S Hoffman, E Franke, J Sacci, E Appella, F V Chisari, L G Guidotti, R W Chesnut, B Livingston, A Sette.   

Abstract

Helper T lymphocyte (HTL) responses play an important role in the induction of both humoral and cellular immune responses. Therefore, HTL epitopes are likely to be a crucial component of prophylactic and immunotherapeutic vaccines. For this reason, Pan DR helper T cell epitopes (PADRE), engineered to bind most common HLA-DR molecules with high affinity and act as powerful immunogens, were developed. Short linear peptide constructs comprising PADRE and Plasmodium-derived B cell epitopes induced antibody responses comparable to more complex multiple antigen peptides (MAP) constructs in mice. These antibody responses were composed mostly of the IgG subclass, reactive against intact sporozoites, inhibitory of schizont formation in liver invasion assays, and protective against sporozoite challenge in vivo. The PADRE HTL epitope has also been shown to augment the potency of vaccines designed to stimulate a cellular immune response. Using a HBV transgenic murine model, it was found that CTL tolerance was broken by PADRE-CTL epitope lipopeptide, but not by a similar construct containing a conventional HTL epitope. There are a number of prophylactic vaccines that are of limited efficacy, require multiple boosts, and/or confer protection to only a fraction of the immunized population. Also, in the case of virally infected or cancerous cells, new immunotherapeutic vaccines that induce strong cellular immune responses are desirable. Therefore, optimization of HTL function by use of synthetic epitopes such as PADRE or pathogen-derived, broadly crossreactive epitopes holds promise for a new generation of highly efficacious vaccines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9844827     DOI: 10.1007/BF02788751

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  130 in total

1.  Delineation of several DR-restricted tetanus toxin T cell epitopes.

Authors:  S Demotz; A Lanzavecchia; U Eisel; H Niemann; C Widmann; G Corradin
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

2.  Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1.

Authors:  J H Brown; T S Jardetzky; J C Gorga; L J Stern; R G Urban; J L Strominger; D C Wiley
Journal:  Nature       Date:  1993-07-01       Impact factor: 49.962

3.  High level expression of the envelope glycoproteins of the human immunodeficiency virus type I in presence of rev gene using helper-independent adenovirus type 7 recombinants.

Authors:  P K Chanda; R J Natuk; B B Mason; B M Bhat; L Greenberg; S K Dheer; K L Molnar-Kimber; S Mizutani; M D Lubeck; A R Davis
Journal:  Virology       Date:  1990-04       Impact factor: 3.616

4.  Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding.

Authors:  T S Jardetzky; J C Gorga; R Busch; J Rothbard; J L Strominger; D C Wiley
Journal:  EMBO J       Date:  1990-06       Impact factor: 11.598

5.  CD4+ subset expression in murine candidiasis. Th responses correlate directly with genetically determined susceptibility or vaccine-induced resistance.

Authors:  L Romani; A Mencacci; E Cenci; R Spaccapelo; P Mosci; P Puccetti; F Bistoni
Journal:  J Immunol       Date:  1993-02-01       Impact factor: 5.422

6.  Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1.

Authors:  M Clerici; J V Giorgi; C C Chou; V K Gudeman; J A Zack; P Gupta; H N Ho; P G Nishanian; J A Berzofsky; G M Shearer
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

7.  Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants.

Authors:  R Cibotti; J M Kanellopoulos; J P Cabaniols; O Halle-Panenko; K Kosmatopoulos; E Sercarz; P Kourilsky
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

Review 8.  T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages.

Authors:  E H Nardin; R S Nussenzweig
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

Review 9.  Regulation of human B-cell activation and adhesion.

Authors:  E A Clark; P J Lane
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

10.  Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.

Authors:  A Vitiello; G Ishioka; H M Grey; R Rose; P Farness; R LaFond; L Yuan; F V Chisari; J Furze; R Bartholomeuz
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

View more
  31 in total

1.  New dimensions in vaccinology: A new insight.

Authors:  D Tomar; V Chattree; V Tripathi; A A Khan; A R Bakshi; D N Rao
Journal:  Indian J Clin Biochem       Date:  2005-01

2.  Two-step functionalization of oligosaccharides using glycosyl iodide and trimethylene oxide and its applications to multivalent glycoconjugates.

Authors:  Hsiao-Wu Hsieh; Ryan A Davis; Jessica A Hoch; Jacquelyn Gervay-Hague
Journal:  Chemistry       Date:  2014-04-08       Impact factor: 5.236

3.  Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients.

Authors:  K L Knutson; K Schiffman; M L Disis
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

4.  Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant.

Authors:  Douglas G McNeel; Keith L Knutson; Kathy Schiffman; Donna R Davis; Dania Caron; Mary L Disis
Journal:  J Clin Immunol       Date:  2003-01       Impact factor: 8.317

5.  Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii.

Authors:  Hua Cong; Ernest J Mui; William H Witola; John Sidney; Jeff Alexander; Alessandro Sette; Ajesh Maewal; Rima McLeod
Journal:  Immunome Res       Date:  2010-12-03

6.  Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity.

Authors:  Lbachir BenMohamed; Georges Bertrand; Cory D McNamara; Helene Gras-Masse; Juergen Hammer; Steven L Wechsler; Anthony B Nesburn
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

Review 7.  Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.

Authors:  Anahit Ghochikyan
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-04       Impact factor: 4.388

Review 8.  HLA-DR: molecular insights and vaccine design.

Authors:  Lawrence J Stern; J Mauricio Calvo-Calle
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

9.  Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits.

Authors:  Anahit Ghochikyan; Hayk Davtyan; Irina Petrushina; Armine Hovakimyan; Nina Movsesyan; Arpine Davtyan; Anatoly Kiyatkin; David H Cribbs; Michael G Agadjanyan
Journal:  Hum Vaccin Immunother       Date:  2013-02-11       Impact factor: 3.452

10.  Enhanced immunogenicity of the modified GP5 of porcine reproductive and respiratory syndrome virus.

Authors:  Liurong Fang; Yunbo Jiang; Shaobo Xiao; Chuanshuang Niu; Hui Zhang; Huanchun Chen
Journal:  Virus Genes       Date:  2006-02       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.